|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Radiation Medicine Centre, Tata Memorial Hospital Annexe, Parel, Mumbai, India
Correspondence: For correspondence or reprints contact: Archi Agrawal, Radiation Medicine Centre, Tata Memorial Hospital, Annexe Building, Jerbai Wadia Rd., Parel, Mumbai, 400 012, India. E-mail: drarchi23{at}hotmail.com
The aim of this study was to see whether oral administration of 18F-FDG could be substitutedwithout significant loss of informationfor intravenous injection of 18F-FDG in patients with difficult intravenous access of any cause, such as that often seen in cancer patients after many cycles of chemotherapy. Methods: PET after both oral and intravenous administration of 18F-FDG was performed on 2 healthy volunteers and 7 patients. An interval of 48 h was maintained between the oral administration and the intravenous administration. All scans were visually analyzed. Semiquantitative analysis of specific areas was done by calculating standardized uptake values (SUVs). Scanning was performed 60 min after intravenous tracer administration and 90 min after oral tracer administration. Results: All lesions seen after intravenous administration were visualized on the oral study as well. SUVs were lower on the oral study than on the intravenous study. Conclusion: Oral 18F-FDG can successfully be substituted for intravenous 18F-FDG in patients with difficult intravenous access. However, because of the large amount of 18F-FDG retained in the gut, careful interpretation will be required when disease of the gastrointestinal tract is being evaluated.
Key Words: difficult intravenous access; oral 18F-FDG; PET scan
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE JOURNAL OF NUCLEAR MEDICINE | JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY |